Meropenem Continuous Infusion in a Septic Patient with Periprosthetic Infection and End-Stage Renal Disease Undergoing Prolonged Intermittent Renal Replacement Therapy
Open Access
Abstract
This case report highlights the use of continuous infusion of meropenem in a 42-year-old septic female patient with periprosthetic infection and end-stage renal disease receiving prolonged intermittent renal replacement therapy (PIRRT). Antibiotic infusion in patients receiving renal replacement therapy has its own peculiarities. There are many studies on the optimal dosing regimen for meropenem in renal dysfunction, but studies on the optimal infusion duration in these patients are limited. The patient was admitted with complaints of wounds, necrosis zones of the right upper limb, restriction of joint movements, and temperature increase up to 38 °C. The patient was treated with a continuous infusion of meropenem 2 g per day receiving renal replacement therapy three times a week (12 h). Also during hospitalization, the patient underwent hip disarticulation and excision of necrotic tissues. The patient was further transferred to a specialized nephrology department for further treatment. We believe that in this clinical case, the use of continuous infusion of meropenem in the complex therapy of sepsis in a patient with CKD undergoing PIRRT sessions helped to lead to clinical improvement in the patient. Further studies are needed.Keywords
This publication has 13 references indexed in Scilit:
- Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical SituationEuropean Journal of Drug Metabolism and Pharmacokinetics, 2021
- Sepsis in end-stage renal disease patients: are they at an increased risk of mortality?Annals of Medicine, 2021
- Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapyJournal of Critical Care, 2020
- Evaluation of Hemodialysis Effect on Pharmacokinetics of Meropenem/Vaborbactam in End‐Stage Renal Disease Patients Using Modeling and SimulationThe Journal of Clinical Pharmacology, 2020
- Population Pharmacokinetic Analysis of Meropenem in Critically Ill Patients With Acute Kidney Injury Treated With Continuous HemodiafiltrationTherapeutic Drug Monitoring, 2020
- Pharmakotherapie bei NiereninsuffizienzMedizinische Klinik - Intensivmedizin und Notfallmedizin, 2018
- Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortalityKidney International, 2016
- Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement TherapyThe Journal of Clinical Pharmacology, 2016
- Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administrationInternational Journal of Antimicrobial Agents, 2015
- Principles of antibacterial dosing in continuous renal replacement therapyCritical Care Medicine, 2009